Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Baxter International Inc. (BAX): One Pharma Stock Investors Should Watch

Baxter International Inc. (NYSE:BAX), one of the fastest-growing healthcare multinational corporations of America, has a long history of strong financial credentials. With a single-point agenda of emerging out as a clear leader in its core area of operations, Baxter International Inc. (NYSE:BAX) has repeatedly proven its might.

Baxter International Inc. (NYSE:BAX)

The FY 2012 growth story

With FY 2012, the company wrapped up another successful business year. It achieved 5 % year-over-year growth in revenue (exclusive of foreign exchange effect) to reach an astounding $14.2 billion. Net income for the year was $2.3 billion and cash flow from operations amounted to $3.1 billion, up 10% year-over-year.

And the story continues ….

Baxter International Inc. (NYSE:BAX) kept up its steady performance in the first quarter of 2013, satisfying Wall Street’s earnings expectations. The company reported net income of $581 million (excluding the special items) registering year-over-year growth of 2%. The adjusted earnings per diluted share were reported at $1.05, up 4% year-over-year, meeting the company’s earnings guidance.

The strategy

The recent past has seen Baxter make strategic acquisitions with a view to gain a competitive advantage and to achieve inorganic growth. The acquisition of Gambro has successfully placed Baxter International Inc. (NYSE:BAX) in the running to achieve the top spot in the renal market space.

In addition, Baxter, through its newly established venture capital arm, has been active in occupying stakes in new entities in the healthcare segments. This will enable the company to enhance its product portfolio and promote development and innovation, which will drive future growth and profitability of the company.

Keeping inline with the above, the company has recently acquired an $8.5 million stake in Ocular Therapeutix, a growing company involved in the development of ophthalmic-therapeutic products, with the intention to achieve a significant competitive edge in the long term.

Furthermore, the company has made a $38 million investment in Naurex, an Evanston, Ill.-based start-up, which develops solutions to treat depression and other nervous system disorders such as Alzheimer’s disease and schizophrenia.

Strengths and opportunities

The demographic transition caused by declining fertility and a lower mortality rate has led to longer lives and an ageing world, which has a direct effect on the demand for healthcare facilities. The rising rates of diabetes and diabetes- induced diseases have created enormous opportunities for the healthcare players to dwell upon.

Baxter International Inc. (NYSE:BAX) healthcare provides unique solutions for critical diseases and has developed successful therapies for treating blood disorders and renal complications.

Source: Annual report 2012

The company has established itself as the world leader in haemophilia care. It has recently launched the first protein-free recombinant factor VIII to treat haemophilia.

Baxter International Inc. (NYSE:BAX) sells its products across 100 countries. Approximately 60% of sales are accounted for by countries other than the United States. The company has a fast-growing base in regions like Latin America, Canada, Asia-Pacific, Europe, Middle East and Africa, which together comprise about 57% of the total markets. This provides enormous opportunity for growth in the developing economies. The medical-products business is comprised of the medical delivery and renal segments, which together account for approximately 56% of the company’s total revenue.

The healthcare giant has developed a diverse portfolio of segments over the years and its continued commitment to innovation and development provide for solid growth prospects going forward.

Competitive Scenario

Fresenius Medical Care AG & Co. (ADR) (NYSE:FMS) is a leading player in the healthcare industry with a market capitalization of $ 21.6 billion. With a diversified business portfolio, Fresenius Medical Care AG & Co. (ADR) (NYSE:FMS) is a tough contender in the healthcare segment. The company beats Baxter to occupy the leading position in dialysis care with Fresenius Medical Care AG & Co. (ADR) (NYSE:FMS), the company’s wholly owned subsidiary specializing in renal care, contributing to about 54 % of the consolidated sales of the group entity.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.